Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ABBOTINDIA

ABBOTINDIA

Abbott India Limited
Mid-capPharma ↗

What the six lenses say about ABBOTINDIA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹25940.0
2026-09-08
VWAP · 1Y anchor
₹27568
-5.9% from VWAP
P/E · TTM
—
no TTM EPS
52-week range
10%
position low→high
RSI(14)
37
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How ABBOTINDIA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
4.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD38›

The actual numbers

Price vs VWAP (1y)-5.9%
EMA trend stackDown · 21<50<200
Price vs 200-EMA-5.2%
Price vs 50-EMA-3.0%
RSI(14)37
RS vs Nifty 500 · 3M-3.8%
RS vs sector · 3M-9.8%
52-week range10%
Volume vs 30d avg1.30×
Volume vs 60d avg1.02×
ATR(14) · volatility500.5
Bollinger width · vol contraction0.092
FundamentalD970›

The actual numbers

Return on equity (ROE)34.5%
Return on capital (ROCE)44.9%
Operating margin30.4%
Net margin22.4%
Revenue growth · YoY+8.1%
EPS growth · YoY+9.7%
Debt / equity0.04×

Full 8-quarter history in the financials table below.

ValuationD836›

The actual numbers

52-week range10%
Catalyst——›

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding75.0%
Delivery · 30d avg56.3%
Up/down-day asymmetry-1.6pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D3 + D6 ) ÷ 2 = 4.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
12
Conviction score 12/100 · avg-decile strength 4.5/10
Conviction score12/100›
TechnicalD3›
FundamentalD9›
ValuationD8›
Catalyst
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.0pp
+1.6pp
-3.4pp
-2.2pp
-2.3pp
-12.2pp
Nifty 500
Broad-market baseline
-0.1pp
+1.6pp
-4.5pp
-3.8pp
-8.1pp
-17.4pp
Sector
Own-sector index
—
—
-7.3pp
-9.8pp
-21.2pp
-38.2pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ABBOTINDIA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
25940.00-125.00

Relative strength

RS vs baseline · rebased to 100

ABBOTINDIA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
88.05-0.05

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

No quarterly financials available.

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

No recent corporate announcements.

Ownership

Who holds ABBOTINDIA

Mutual funds holding ABBOTINDIA (10)

FundWeightAUM ₹crGrade
Nippon India Multi Cap Dir Bns0.63%55,587
Nippon India Multi Cap Gr0.63%55,587
Nippon India Multi Cap Bns0.63%55,587
SBI Large & Midcap Reg Gr2.02%42,325
Axis Midcap Gr1.32%34,404
Canara Robeco Large & Mid Cap Reg Gr1.41%26,062
Canara Robeco Flexi Cap Reg Gr0.60%13,615
PGIM India Midcap Fund Reg Gr0.83%11,071
Nippon India Pharma Gr2.24%9,279
Nippon India Pharma Bns2.24%9,279

ETFs holding ABBOTINDIA (7)

ETFWeightGrade
Nippon India Nifty Pharma ETF1.46%
DSP Nifty Healthcare ETF1.28%
ICICI Pru Nifty Healthcare ETF1.26%
Aditya BSL Nifty Healthcare ETF1.26%
Axis NIFTY Healthcare ETF1.25%
Mirae Asset Nifty 500 Healthcare ETF1.03%
Motilal Oswal BSE Healthcare ETF0.88%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma